Drew Angerer/Getty Images News UMB Financial plans to refile a $6.4 billion against Bristol-Myers Squibb by shareholders owning contingent value rights over its acquisition of Celgene. UMB plans to refile a lawsuit by the end of next week, according to a CTFN report on.
